KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Income from Continuing Operations for 15 consecutive years, with 4068000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 126.46% to 4068000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 38550000.0, a 152.11% decrease, with the full-year FY2025 number at 38550000.0, down 152.19% from a year prior.
  • Income from Continuing Operations was 4068000.0 for Q4 2025 at Supernus Pharmaceuticals, up from 45154000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 38543000.0 in Q3 2024 to a low of 45154000.0 in Q3 2025.
  • A 5-year average of 7542300.0 and a median of 6776000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 2508.22% in 2024, then crashed 8370.63% in 2025.
  • Supernus Pharmaceuticals' Income from Continuing Operations stood at 2442000.0 in 2021, then skyrocketed by 943.16% to 25474000.0 in 2022, then crashed by 95.54% to 1137000.0 in 2023, then skyrocketed by 1252.42% to 15377000.0 in 2024, then tumbled by 126.46% to 4068000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Income from Continuing Operations are 4068000.0 (Q4 2025), 45154000.0 (Q3 2025), and 22499000.0 (Q2 2025).